These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 25139038)
1. Balance of antiangiogenic and angiogenic factors in the context of the etiology of preeclampsia. Seki H Acta Obstet Gynecol Scand; 2014 Oct; 93(10):959-64. PubMed ID: 25139038 [TBL] [Abstract][Full Text] [Related]
2. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Saad AF; Kechichian T; Yin H; Sbrana E; Longo M; Wen M; Tamayo E; Hankins GD; Saade GR; Costantine MM Reprod Sci; 2014 Jan; 21(1):138-45. PubMed ID: 23749761 [TBL] [Abstract][Full Text] [Related]
3. Angiogenic Imbalance as a Contributor of Preeclampsia. Dymara-Konopka W; Laskowska M; Błażewicz A Curr Pharm Biotechnol; 2018; 19(10):797-815. PubMed ID: 30255753 [TBL] [Abstract][Full Text] [Related]
4. Preeclampsia: new insights. Shah DM Curr Opin Nephrol Hypertens; 2007 May; 16(3):213-20. PubMed ID: 17420664 [TBL] [Abstract][Full Text] [Related]
5. Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. Tong S; Kaitu'u-Lino TJ; Onda K; Beard S; Hastie R; Binder NK; Cluver C; Tuohey L; Whitehead C; Brownfoot F; De Silva M; Hannan NJ Hypertension; 2015 Nov; 66(5):1073-81. PubMed ID: 26324507 [TBL] [Abstract][Full Text] [Related]
6. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. Masuyama H; Nakatsukasa H; Takamoto N; Hiramatsu Y J Clin Endocrinol Metab; 2007 Jul; 92(7):2672-9. PubMed ID: 17426083 [TBL] [Abstract][Full Text] [Related]
7. Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity. Palmer KR; Kaitu'u-Lino TJ; Hastie R; Hannan NJ; Ye L; Binder N; Cannon P; Tuohey L; Johns TG; Shub A; Tong S Hypertension; 2015 Dec; 66(6):1251-9. PubMed ID: 26416849 [TBL] [Abstract][Full Text] [Related]
11. Biology of preeclampsia: Combined actions of angiogenic factors, their receptors and placental proteins. Huppertz B Biochim Biophys Acta Mol Basis Dis; 2020 Feb; 1866(2):165349. PubMed ID: 30553017 [TBL] [Abstract][Full Text] [Related]
12. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles. Alahakoon TI; Zhang W; Trudinger BJ; Lee VW J Matern Fetal Neonatal Med; 2014 Dec; 27(18):1854-9. PubMed ID: 24397483 [TBL] [Abstract][Full Text] [Related]
13. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Cudmore M; Ahmad S; Al-Ani B; Fujisawa T; Coxall H; Chudasama K; Devey LR; Wigmore SJ; Abbas A; Hewett PW; Ahmed A Circulation; 2007 Apr; 115(13):1789-97. PubMed ID: 17389265 [TBL] [Abstract][Full Text] [Related]
14. Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia. Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Nguyen TV; Tuohey L; Cluver C; Tong S; Kaitu'u-Lino TJ Placenta; 2020 Jun; 95():78-83. PubMed ID: 32452405 [TBL] [Abstract][Full Text] [Related]
15. New developments in the pathogenesis of preeclampsia. Naljayan MV; Karumanchi SA Adv Chronic Kidney Dis; 2013 May; 20(3):265-70. PubMed ID: 23928392 [TBL] [Abstract][Full Text] [Related]
16. Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia. Brownfoot FC; Tong S; Hannan NJ; Binder NK; Walker SP; Cannon P; Hastie R; Onda K; Kaitu'u-Lino TJ Hypertension; 2015 Sep; 66(3):687-97; discussion 445. PubMed ID: 26222708 [TBL] [Abstract][Full Text] [Related]
17. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Lim JH; Kim SY; Park SY; Yang JH; Kim MY; Ryu HM Obstet Gynecol; 2008 Jun; 111(6):1403-9. PubMed ID: 18515525 [TBL] [Abstract][Full Text] [Related]
18. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia. Leaños-Miranda A; Campos-Galicia I; Ramírez-Valenzuela KL; Chinolla-Arellano ZL; Isordia-Salas I Hypertension; 2013 May; 61(5):1118-25. PubMed ID: 23460287 [TBL] [Abstract][Full Text] [Related]
19. [New insights into the pathogenesis of pre-eclampsia: the role of angiogenesis-inhibiting factors]. Verdonk K; Visser W; Steegers EA; Kappers M; Danser AH; van den Meiracker AH Ned Tijdschr Geneeskd; 2011; 155():A2946. PubMed ID: 21486506 [TBL] [Abstract][Full Text] [Related]
20. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer. Foidart JM; Schaaps JP; Chantraine F; Munaut C; Lorquet S J Reprod Immunol; 2009 Nov; 82(2):106-11. PubMed ID: 19853925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]